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ORIGINAL ARTICLE
Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA
and Transcriptome Changes Indicate Mechanistic Differences to
Azathioprine Alone
Sally A. Coulthard, PhD,* Phil Berry, BSc,† Sarah McGarrity, PhD,† Simon McLaughlin, MD,‡,§
Azhar Ansari, MD,k,¶ and Christopher P. F. Redfern, PhD†
Background: Use of azathioprine (AZA) for inflammatory bowel disease is limited by side effects or poor efficacy. Combining low-dose azathioprine
with allopurinol (LDAA) bypasses side effects, improves efficacy, and may be appropriate as first-line therapy. We test the hypothesis that standard-dose
azathioprine (AZA) and LDAA treatments work by similar mechanisms, using incorporation of the metabolite deoxythioguanosine into patient DNA,
white-blood cell counts, and transcriptome analysis as biological markers of drug effect.
Methods: DNA was extracted from peripheral whole-blood from patients with IBD treated with AZA or LDAA, and analyzed for DNA-incorporated
deoxythioguanosine. Measurement of red-blood cell thiopurine metabolites was part of usual clinical practice, and pre- and on-treatment (12 wk) blood
samples were used for transcriptome analysis.
Results: There were no differences in reduction of white-cell counts between the 2 treatment groups, but patients on LDAA had lower DNA-
incorporated deoxythioguanosine than those on AZA; for both groups, incorporated deoxythioguanosine was lower in patients on thiopurines for 24
weeks or more (maintenance of remission) compared to patients treated for less than 24 weeks (achievement of remission). Patients on LDAA had higher
levels of red-blood cell thioguanine nucleotides than those on AZA, but there was no correlation between these or their methylated metabolites, and
incorporated deoxythioguanosine. Transcriptome analysis suggested down-regulation of immune responses consistent with effective immunosuppression
in patients receiving LDAA, with evidence for different mechanisms of action between the 2 therapies.
Conclusions: LDAA is biologically effective despite lower deoxythioguanosine incorporation into DNA, and has different mechanisms of action
compared to standard-dose azathioprine.
(Inflamm Bowel Dis 2017;0:1–10)
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A zathioprine, a thiopurine prodrug of 6-mercaptopurine(6-MP), is an established long-term, safe, and effective treat-
ment for inflammatory bowel disease (IBD). However, many
patients suffer from thiopurine-related side effects, including
hepatotoxicity, which the coadministration of low-dose azathio-
prine with the xanthine oxidase inhibitor allopurinol (LDAA) is an
accepted strategy for avoiding.1,2 The clinical use of LDAA in-
cludes patients who develop abnormal liver function tests or side
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effects to standard-dose azathioprine or 6-MP. It is also used in
a few patients with a poor response to azathioprine/6-MP, and
a specific metabolite profile characterized by high methylated
metabolite (MMP) and low thioguanine nucleotide (TGNs) levels
in red-blood cells (RBC).3,4 This “hypermethylation” profile may
result from preferential methylation of 6-MP by thiopurine meth-
yltransferase (TPMT) to MMP (Fig. 1), giving a poor clinical
response and increased chance of hepatotoxicity.5–8 Methylated
thiopurine metabolites make an important contribution to thiopur-
ine toxicity9; patients with a hypermethylator profile or hepato-
toxicity respond to LDAA with an increase in RBC TGNs,
a reduction in RBC MMP, and disease remission.4,10,11
In a recent open-label study, Pavlidis et al12 treated a cohort
of thiopurine-naive IBD patients with LDAA, dose-adjusted for
TPMT status, and without prior selection based on RBC metabolite
levels. Clinical response in that study was seen in 45/57 (79%)
patients with Crohn’s disease and 34/53 (64%) patients with ulcer-
ative colitis/IBD-unclassified, with remission rates of 61% and 53%
of patients, respectively. This is further evidence that the use of
LDAA both in hypermethylators3,4,10,11 and when used as a first-
line therapy without metabolic screening12 is an effective clinical
strategy comparable to established guidelines for IBD.13
The aim of this pilot study was to test the hypothesis that
the AZA and LDAA treatment strategies are equivalent in terms
of biological markers of thiopurine effect. As markers, we have
investigated the utility of DNA-incorporated deoxythioguanosine
(dTGDNA) in comparison with RBC TGN measurement and
reduction in neutrophil and white blood-cell counts. In addition,
we have used transcriptome analysis to test the hypothesis that
similar biological processes are altered by the different thiopurine-
dosing strategies.
METHODS
Chemicals and Enzymes
The deoxythioguanosine (dTG) standard was from Carbo-
synth (Compton, United Kingdom); deoxyadenosine (dA)
was from Sigma-Aldrich and deuterated methylmercaptopurine
(internal standard) from Toronto Research Chemicals (Ontario,
Canada). HPLC-grade formic acid was from Fisher Scientific
(Loughborough, United Kingdom). All other reagents were from
Sigma (Gillingham, United Kingdom). Calf intestinal alkaline
phosphatase and nuclease P1 from Penicillium citrinum were from
Sigma.
Study Population and Sample Collection
Clinical samples were provided from adult IBD patients treated
with either AZA or LDAA at 8 centers in the UK (see Table 1,
Supplemental Digital Content 1, http://links.lww.com/IBD/B503).
Patients treated with LDAA were from East Surrey Hospital
(ESH) where patients were normally treated with LDAA as
a first-line therapy, and without preselection based on RBC me-
tabolites.12 The numbers of adult patients (ESH patient numbers
in parentheses) being treated for IBD comprized 81 (43) with
Crohn’s Disease, 57 (28) with ulcerative colitis, 4 (1) with inde-
terminate colitis, and 3 (3) with microscopic colitis. At all cen-
ters, patients treated with AZA were treated according to
standard clinical guidelines.13 Of the 145 patients, 84 (50
AZA and 34 LDAA patients) were not prescribed other medica-
tion; the remaining 61 patients were receiving a variety of addi-
tional drugs, including mesalamine (5-aminosalicylic acid; 34
patients), infliximab (4 patients, 1 of whom was receiving mesal-
amine as well) and/or steroids (prednisolone; 3 in the LDAA
group and 7 in the AZA group); other drugs included statins,
antidepressants, and proton pump inhibitors. Data were analyzed
only with respect to thiopurine treatment status, using patients
treated with LDAA at ESH, and patients treated with AZA
across all centers; to avoid bias, LDAA/AZA data from ESH
were also analyzed separately. As part of routine clinical prac-
tice some participating centers requested RBC thiopurine metab-
olite measurements (RBC-TGN and RBC-MMP) at the same
time as samples were taken for dTGDNA analysis; most (92%)
of the samples with these data were from ESH.
Ethical Statement
The study protocol was approved by NRES Committee
South West—Cornwall & Plymouth, Bristol Research
FIGURE 1. Schematic outline of thiopurine metabolism. Azathioprine
is nonenzymatically cleaved to 6-MP which is metabolized by the
enzymes (blue text) inosine-monophosphate dehydrogenase (IMPDH),
thiopurine methyltransferase (TPMT), hypoxanthine-guanine phos-
phoribosyl transferase (HGPRT), inosine tri-phosphatase (ITPase) and
guanosine monophosphate synthetase (GMPS). MeMP, methyl-
mercaptopurine; TIMP, thioinosine monophosphate with metabolism
to the di- and triphosphates TIDP and TITP, respectively; TXMP, thio-
xanthine monophosphate; TGMP, thioguanosine monophosphate
with metabolism to the di- and triphosphates TGDP and TGTP,
respectively, and incorporation into DNA. 6-MP is inactivated by
metabolism to thioxanthine then thiouric acid via xanthine oxidase
(XO), which is inhibited by allopurinol. Thioxanthine may inhibit TPMT.
The molecular mechanism of TGN immunosuppression may include
G-protein (rac-1) inhibition.
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Ethics Committee Centre, and each patient gave written
informed consent.
Sample Preparation and LC-MS/MS Analysis
of Deoxythioguanosine Incorporated in
DNA (dTGDNA)
DNA was isolated from whole blood collected in EDTA
tubes, using previously published methods,14 and the ratio of dTG
relative to dA in DNA (expressed as the number of moles of dTG/
1 · 106 moles of dA) was analyzed using a recently developed
HPLC-mass spectrometry method.15 Briefly, chromatographic
separation of dTG and dA was with a XSelect HSS T3 3.5 mm
4.6 · 100 mm (Waters) column with a VanGuard 3.5 mm 3.9 · 5-
guard column maintained at 308C. Analytes were eluted with
mobile phases of 0.01 M aqueous 0.05% formic acid (A) and
0.05% formic acid in acetonitrile (B). The flow rate was 0.5
mL/minute, and the mobile phase system consisted of a starting
condition of 1% buffer B increasing to 3% at 1.1 minutes, 8% at
2.4 minutes, and increasing to a maximum of 30% at 4.1 minutes
then decreasing to 5% at 4.5 minutes, maintained until 5.5 minutes
then decreasing to 1% for an equilibration period of 2.5 minutes.
Standards ranged from 100 mg/mL dA and 2000 ng/mL dTG and
were serially diluted in water to 0.39 mg/mL dA and 3.9 ng/mL
dTG, respectively. High (40,000 ng/mL dA:400 ng/mL dTG),
medium (4000 ng/mL dA:40 ng/mL dTG) and low (400 ng/mL
dA:4 ng/mL dTG) matrix controls were prepared in triplicate.
Standards, matrix controls, and samples were injected in a volume
of 50 mL; for sample injections this is equivalent to 0.2 mg patient
DNA per injection.
RNA-seq Methods
Patients for RNA-seq analysis were being treated with the
appropriate drug, were in clinical remission at 12 weeks, and for
whom a pretreatment blood sample was available; samples for
analysis were selected “blind” from the pool of patient samples
that met these criteria. At the time of selection, other clinical data
for the patients were not available. RNA-seq of total RNA from
whole blood, collected into Tempus RNA tubes, was performed
by AROS Applied Biotechnology (Aarhus, Denmark). Sequenc-
ing libraries were prepared in 2 batches, LDAA patients and AZA
patients, each batch consisting of 10 samples representing 1 pre-
treatment and 1 post-treatment sample (12 weeks after initiation of
thiopurine therapy) from each patient. Input RNA was 400 ng
from each sample, and libraries were prepared using the Illumina
TruSeq Stranded mRNA LT Sample preparation kit after frag-
mentation using the alternative Illumina fragmentation protocol
and RiboZero rRNA depletion. Libraries were quality controlled
with respect to concentration and size profile. Size profiles (Agi-
lent Bioanalyzer) from samples tested were 300 to 700 bp; library
and library pool concentrations were determined using the KAPA
qPCR kit in triplicate reactions with 3 independent 1 · 106-fold
dilutions of libraries. RNA-seq libraries were sequenced on a Hi-
Seq 2500 using Illumina SBS v4 chemistry using a paired-end
100-bp protocol. Base calls were converted and demultiplexed
according to the sequencing primer barcodes, using Illumina
CASAVA software, into FASTQ files. Paired-end reads (100
bp) in FASTQ files were aligned to UCSC hg19 using Bowtie
2.216 and Tophat 2.0.1317 running under Linux (Ubuntu). Align-
ments were counted using Bioconductor R packages “Genomi-
cRanges” and “GenomicAlignments.”
Statistical Analyses
All statistical analyses were conducted using R 3.1.2 and
3.3.0.18 We regard these analyses as exploratory and have not
applied corrections for experiment-wise error rate in rank corre-
lation and rank sum tests applied to different variable and data
subsets. Nonparametric methods (2-sided; Kendall’s Rank Corre-
lation, Asymptotic Wilcoxon Mann–Whitney Rank Sum Test,
Kruskal-Wallis Test) were used for basic analyses of thiopurine
metabolites and clinical correlates. Parametric methods (1- and
2-sample [Welch’s] t tests) were used where data were normally
distributed (Shapiro-Wilks test). For analysis of dTGDNA at dif-
ferent times after treatment initiation, patients were divided into 2
groups: treatment time for 4 to 167 days and .167 days; the
boundary at 167 days (24 wk) represents times to achieve remis-
sion (#167 d) and maintenance of remission (.167 d) used in
a recent clinical study.19
Gene-count data from RNA-seq studies were analyzed using
a mixed-effect approach in “edgeR” to derive treatment effects
(post/pre) across all patients in each group (standard-dose azathio-
prine, AZA, and low-dose azathioprine with allopurinol, LDAA).20
Genes .1.5-fold over- or underexpressed in response to drug treat-
ment (Benjamini-Hochberg False Discovery Rate [BH FDR] ,
0.05) were mapped separately to Gene Ontology (GO) biological
processes using “goseq” in R. For the goseq analysis, a BH FDR of
,0.001 was applied to the LDAA data and,0.05 to the AZA data.
The lists of statistically significant GO terms returned by goseq
were summarized graphically using the web resource Revigo,21
using a similarity cutoff of 0.7, and Cytoscape.22 Robustness of
the goseq analyses was tested by applying a jack-knife procedure,
running the goseq analysis on the edgeR output after excluding
each patient in turn. Summary lists of genes differentially expressed
in common with both treatments were mapped to GO terms using
“BiomaRt” in R and the GO terms summarized using Revigo using
a similarity score of 0.4.
RESULTS
Incorporation of dTG into DNA of Nucleated
Blood Cells
Eighteen samples with data on white blood-cell counts were
received from newly diagnosed patients with IBD at initiation of
treatment with AZA or LDAA (9 patients per group); these
patients were not prescribed additional medication. Twelve weeks
after initiation of therapy, there was a significant reduction in
neutrophil and white-blood cell counts (Fig. 2; 1-sample t test,
P# 0.003, n ¼ 18); 3 patients in the AZA group were leukopenic
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(white-blood cell counts , 4 · 109/L). There was no significant
difference in reduction of neutrophil or white-blood cell count
between the 2 drug regimens (Welch’s t test; P $ 0.64), although
dTGDNA for patients in the LDAA group was significantly lower
(Mann–Whitney test, P ¼ 0.03; Fig. 2).
For the dataset as a whole, dTGDNA was also lower in the
patients receiving LDAA compared with those on AZA
(Mann–Whitney test, Z ¼ 2.95, P ¼ 0.003; Fig. 3), but there
was no significant difference in white-blood cell counts between
the 2 treatments (Mann–Whitney, P ¼ 0.65). With respect to time
of treatment, dTGDNA levels in patients receiving either AZA or
LDAA for more than 24 weeks (.167 d; maintenance of remis-
sion) were lower than for patients who had received therapy for
up to 24 weeks (4–167 d; achievement of clinical remission)
FIGURE 2. Changes in white blood-cell counts (A), neutrophil counts (B), and levels of dTGDNA (C) in newly diagnosed patients at 12 weeks after
therapy with AZA or LDAA. The data show a significant reduction in mean white-cell and neutrophil counts (neutrophils in brackets) from 9.3 (6.4)
to 6.6 (4.4) as a result of therapy with AZA or LDAA (n ¼ 18; one-sample t-test on difference per patient, P # 0.001), but no significant difference
between the AZA or LDAA treatments (t-test; P $ 0.64). However, there were significantly lower dTGDNA levels in the LDAA group (Mann–Whitney
Rank Sum Test, Z ¼ 2.21, P ¼ 0.03). Units: neutrophil and white blood-cell counts · 109/L; dTGDNA, moles dTG/106 moles dA.
FIGURE 3. A, Box and whisker plot of data for dTGDNA in the AZA and LDAA treatment groups for all patients in the study and sampled at different
periods on therapy. For AZA (all sites) median dTGDNA was 139.6 (mean 241.5, range 0–1857, SD 310.7, n ¼ 97) and for LDAA-treated patients (ESH)
37.6 (mean 128.8, range 0–839.3, SD 184.5, n ¼ 48). For comparison, AZA-treated patients at ESH alone had median dTGDNA 173.1 (mean 308.7,
range 0–1384.5, SD 399.4, n ¼ 27). B, Box and whisker plot for dTGDNA in 2 time periods: 4 to 167 days (;# 24 wk) and . 167 days (.24 wk),
representing time to achievement of remission, and maintenance of remission.19 Initial assessment of dTGDNA by time periods at 4 to 83, 84 to 167,
168 to 252, or .252 days after initiation of therapy suggested a decrease after 167 days (see Fig. 1, Supplemental Digital Content 1, http://links.
lww.com/IBD/B503); therefore, periods 1 and 2, and 3 and 4 were combined for analysis. The distributions of treatment times were similar for AZA
and LDAA-treated patients. Units: dTGDNA, moles dTG/106 moles deoxyadenosine.
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(P # 0.01 for all data and ESH data alone; Fig. 3). There were
no patients deficient in TPMT activity (,10 mU/L), and no
relationship between dTGDNA and patient TPMT activity,
either for the whole dataset or each drug treatment group alone
(Kendall, P . 0.5).
Patients on LDAA received azathioprine at approxi-
mately one-quarter the dose of those on AZA (median 40.5
mg [range 15–75], and 125 mg [range 22–250] per day, aver-
aged across a week, for LDAA and AZA, respectively). For
patients receiving AZA, there was a significant correlation
between dose and dTGDNA (P ¼ 0.012, Table 1), but this
was marginal for LDAA patients (P ¼ 0.073). In some patients
within both AZA and LDAA treatment groups, dTGDNA was
below the level of detection; for the 12 patients with undetect-
able dTGDNA where RBC TGN measurements were available,
RBC TGN levels ranged between 194 and 1016 pmol/8 · 108
RBC, indicating that undetectable dTGDNA was not a result of
poor compliance. Furthermore, there were no differences in
white-blood cell counts between patients with detectable
dTGDNA and those without (Mann–Whitney, P ¼ 0.96, AZA
and LDAA groups combined).
RBC Metabolites and Relationships
with dTGDNA
With respect to the relationships between RBC-TGNs and
-MMPs, there was no correlation between RBC-TGN and RBC-
MMP for LDAA patients, but the converse was true for AZA.
However, there was a significant positive correlation between
prescribed azathioprine dose and RBC-MMP levels for LDAA
but not for AZA. Conversely, RBC-TGN showed no correlation
with thiopurine dose for either AZA or LDAA. Finally, no
significant relationship was apparent between dTGDNA and
RBC-TGNs or RBC-MMPs for patients on AZA or LDAA
(Table 1).
RBC-TGN levels differed between patients in the 2 drug
groups with patients on LDAA having higher median RBC-TGN
levels (Mann–Whitney test, P ¼ 0.008), although the effect was
not significant for the ESH data alone (P ¼ 0.062; Table 2).
TABLE 1. Probabilities for Kendall Rank Correlations
Between Azathioprine Dosea, RBC TGN, RBC MMP and
dTGDNA for the AZA (a) and LDAA (b) Drug Treatment
Groups (n ¼ 97 and 48, Respectively)
Dose
TGN MMP dTGDNA
(a) AZA
Dose NS (0.6) NS (0.07) 0.012*
TGN ,0.02* NS (0.6)
MMP NS (0.67)
(b) LDAA
Dose NS (0.55) ,0.007** 0.073
TGN NS (0.53) NS (0.73)
MMP NS (0.3)
aDaily prescribed dose, averaged per week, not adjusted for body mass.
NS, non-significant (P values in brackets).
P , 0.1; *P , 0.05; **P , 0.01.
TABLE 2. RBC-TGNs and MMP Measurements by
Treatment Group
Drug Median Mean Range SD n
(a) TGN
AZA 288.0 311.7 0–942 194.0 24
LDAA 452.0 486.8 101–1645 296.1 41
(b) MMP
AZA 233.0 1788.4 0–12,673 3260.3 23
LDAA 163.0 762.8 0–18,307 2907.4 40
For RBC TGNs (a), levels were significantly higher in LDAA-treated patients (LDAA at
ESH versus AZA across all sites, Mann–Whitney Rank Sum Test, Z ¼ 22.64, P ¼
0.008), but this was not the case for LDAA versus AZA at ESH (P ¼ 0.062). With respect
to RBC MMPs, measurements did not differ significantly between treatment groups,
either for the dataset overall or at ESH (Mann–Whitney Rank Sum Test, Z ¼ 1.1, P $
0.26). Units: pmoles/8 · 108 RBC.
TABLE 3. RNA-seq Samples
Patient dTGDNA Drug RBC-TGN Diagnosis
DCH01 61.1 AZA nd UC
DCH02 1003.3 AZA nd UC
NT19 116.8 AZA nd UC
RCH27 377.8 AZA nd CD
RCH08 3.5 AZA nd UC
Mean 312.5 AZA
Median 116.8 AZA
Patient dTGDNA Drug RBC-TGN Diagnosis
ESH19 279.6 LDAA 549 CD
ESH28 1384.53 LDAA 407 CD
ESH24 162.2 LDAA 230 UC
ESH20 39.7 LDAA 214 UC
ESH54 0 LDAA 238 CD
Mean 373.2 LDAA
Median 162.2 LDAA
Note that for one patient, the “pretreatment” sample for RNA was taken 11 days after
initiation of therapy, but the analysis was unaffected by inclusion of this as a time-zero
sample. Units: dTGDNA, moles dTG/106 moles deoxyadenosine (dA); RBC-TGN, Units:
pmoles/8 · 108 RBC. LDAA patients were not receiving additional medication; in con-
trast, of the AZA patients, one was also being treated with cyclosporin, mesalamine and
prednisolone, one with mesalamine and one was also being treated with infliximab.
CD, Crohn’s Disease; nd, not determined; UC, ulcerative colitis.
Inflamm Bowel Dis  Volume 0, Number 0, Month 2017 Azathioprine with Allopurinol for IBD
www.ibdjournal.org | 5
Although median and mean RBC-MMP levels were lower in the
LDAA group, this difference was not statistically significant (P $
0.26). In contrast to dTGDNA measurements, there was no
difference between the early and late time periods of treatment
for either RBC metabolite (Mann–Whitney Rank Sum Test, P $
0.35).
FIGURE 4. GO profiling from RNA-seq data for thiopurine-treated patients: (A) biological processes significantly associated with genes under-
expressed as a consequence of LDAA therapy; (B) sampled (jack-knife: each patient excluded in turn) data, biological processes significantly
associated with underexpressed genes in LDAA-treated patients which were common to all subsampled sets; (C) biological processes significantly
associated with over-expressed genes in LDAA-treated patients; (D) biological processes significantly associated with overexpressed genes which
were common to all subsampled sets of LDAA-treated patients; in A to D, the BH FDR was set to P , 0.001 for GO categories. E, GO profiling from
RNA-seq data for AZA-treated patients, showing biological processes significantly associated with underexpressed genes (BH FDR was set to P ,
0.05 for GO categories). No biological processes were significantly associated with increases in gene expression in response to AZA, but only the
GO cell compartments “cell periphery” and “plasma membrane,” were significantly associated with increases in gene expression in response to
AZA and these were common to all subsamples.
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Transcriptome Changes as Markers of
Biological Response to Thiopurine Therapy
For 10 newly diagnosed patients, blood samples for tran-
scriptome analysis by RNA-seq were collected prior to thiopurine
therapy, and a second sample collected from each patient after 12
weeks of treatment with either AZA alone or LDAA; for these
patients, 5 treated with AZA and 5 with LDAA, no adverse drug
reactions were recorded, and all were in clinical remission. The
time of sampling was consistent with achievement of maximal
levels of dTGDNA and 9 of the 10 patients had detectable
dTGDNA; mean and median dTGDNA levels were similar in the
2 groups. The patient without detectable dTGDNA was receiving
LDAA and RBC-TGN levels indicated compliance (Table 3). All
LDAA patients were from 1 site (ESH) and were not on additional
medication, whereas, the AZA patients were from 3 separate sites
and some were receiving additional drugs (Table 3). For the
LDAA patient group overall, 619 genes were repressed and 614
had higher expression in response to therapy (seeTables S2 and
S3, Supplemental Digital Content 1, http://links.lww.com/IBD/B503);
applying a BH FDR of ,0.001 for Gene Ontology (GO) analysis of
gene lists, underexpressed genes were significantly associated with
biological processes of immune defense (Fig. 4; see Table S4, Sup-
plemental Digital Content 1, http://links.lww.com/IBD/B503). Sub-
sampling by reanalysis after exclusion of each patient in turn revealed
a core set of biological-process GO categories comprising “defence
response” (GO:0006952), “defence response to other organism”
(GO:0098542) and “immune response” (GO:0006955). GO
biological-process categories significantly associated with overex-
pressed genes in the LDAA-treated patients were more diverse, with
subsampling giving RNA metabolic processes and processes of mac-
romolecular localization and organization as the GO category core
sets for biological processes (Fig. 4; see Table S5, Supplemental
Digital Content 1, http://links.lww.com/IBD/B503). Within the
top 5 genes repressed by LDAA (lowest P values), SNRK-AS1
is potentially involved in colon-cell proliferation, PLTP modulates
inflammation and immune responses and C1orf56 (MENT) is
a tumor modifier associated with lymphoma; the top 5 overex-
pressed genes were associated with activation of host-defense re-
sponses and hematopoiesis (see Tables S2 and S3, Supplemental
Digital Content 1, http://links.lww.com/IBD/B503).
For the AZA-treated group, 464 genes were repressed and 165
had higher expression in response to therapy (see Tables S6 and S7,
Supplemental Digital Content 1, http://links.lww.com/IBD/B503). In
these gene lists, there was no significant representation in any GO
categories at a BH FDR of ,0.001. At an FDR of ,0.05, underex-
pressed genes were enriched in diverse GO categories, particularly
those concerned with ion transport and homeostasis, proteolysis and
protein catabolism, and cell-cycle regulation (Fig. 4; see Table S8,
Supplemental Digital Content 1, http://links.lww.com/IBD/B503).
The RNA-seq data for the AZA patient group as a whole were
less consistent than the LDAA group; 3 of the 5 jack-knife
subsamples for underexpressed genes had no significant GO
categories. Overexpressed genes in the complete AZA dataset
fell into only 2 GO categories: plasma membrane and cell
periphery cell compartments, with no representation in
biological-process GO categories; these GO cell-compartment
categories were also common to all subsamples. However, over-
expressed genes in 3 of the 5 subsamples were involved in
regulation of cell activation and immune system biological pro-
cesses (see Table S9, Supplemental Digital Content 1, http://
links.lww.com/IBD/B503).
The RAC1 GTPase is thought to be a target of thiopurines23
but was not represented in the lists of genes differentially expressed in
response to therapy (see Tables S2, S3, S6, and S7, Supplemental
Digital Content 1, http://links.lww.com/IBD/B503). Furthermore, GO
terms associated with RAC1 function (http://www.genecards.org/cgi-
bin/carddisp.pl?gene¼RAC1) were not included in the lists of GO
terms significantly associated with differentially expressed genes.
Thirty repressed and 27 overexpressed genes were common
to both treatments (see Table S10, Supplemental Digital Content
1, http://links.lww.com/IBD/B503). Amongst the common under-
expressed genes we highlight guanylate cyclase 2C (GUCY2C),
a gene predominantly expressed in colon epithelial cells24 which
was repressed by up to 2.5-fold (LDAA: P , 0.0001; AZA: P ¼
0.03). After mapping to GO terms and summarizing the GO term
lists, common over- and underexpressed genes were associated
mainly with oxidation-reduction processes (GO:0055114; fre-
quency .15% of genes). In addition, underexpressed genes were
also associated with DNA metabolic (GO:0006259; 6.3%) and
phosphorylation (GO:0016310; 6.3%) processes, and overex-
pressed genes (see Table S11, Supplemental Digital Content,
http://links.lww.com/IBD/B503) with processes of transport
(GO:0006810; 17.4%), carbohydrate metabolism (GO:0005975;
6%), stress response (GO:0006950; 4.1%), and nucleic acid phos-
phodiester bond hydrolysis (GO:0090305; 2.5%).
DISCUSSION
These data confirm the measurable incorporation of
thioguanine nucleotides into the DNA of nucleated blood cells
of patients with IBD on thiopurine therapy. A clinical effect of
thiopurines is the reduction of neutrophil and white cell
counts25–27 which was clearly demonstrated with no difference
between AZA and LDAA treatment groups; in contrast,
dTGDNA levels were lower in LDAA-treated patients, as shown
by the treatment group sampled after 12 weeks of therapy and
the full study dataset. Given correlations between thiopurine
dose and dTGDNA within treatments, lower dTGDNA levels in
the LDAA group may reflect the lower thiopurine dose. These
data suggest that the biological effects of AZA or LDAA are
independent of dTGDNA levels in nucleated blood cells, in
agreement with other studies showing no correlation between
dTGDNA and white-blood cell counts.28 Maximum dTGDNA
levels were in patients sampled within 24 weeks of the start
of therapy, with lower levels in patients sampled at longer
times after therapy initiation; lower levels of dTGDNA on main-
tenance of remission may result from adaptation to thiopurines
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with respect to pathways of metabolism and rates of cell
renewal in relevant target tissues.
In contrast to a previous study,28 we found no significant
correlation between dTGDNA and RBC-TGNs or RBC-MMPs.
Furthermore, RBC-TGN levels were higher in LDAA-treated pa-
tients, in contrast to the lower dTGDNA levels in this patient
group. Our current understanding is that inhibition of xanthine
oxidase by allopurinol reduces the metabolic inactivation of thi-
opurines, allowing more conversion to TGNs.29 MMPs, methyl-
ation products of TPMT activity, decrease in the presence of
allopurinol by an unknown mechanism; TPMT inhibition by an
allopurinol metabolite30 or the 6-MP metabolite thioxan-
thine,29,31,32 have been suggested, and depletion of phosphoribo-
sylpyrophosphate or competitive inhibition of membrane
transport processes are possible alternative mechanisms.33
Clearly, in our study the RBC-TGN and RBC-MMP levels varied
between the AZA and LDAA treatment groups as expected.
It may be paradoxical that dTGDNA levels in nucleated
blood cells of LDAA-treated patients were low despite higher
levels of RBC TGNs compared to patients treated with AZA.
Nucleoside triphosphates are toxic to cells,34 and homeostatic
mechanisms may counter raised TGTP levels by conversion of
nucleoside triphosphates to monophosphates, as we have found
with TGTP in vitro (Coulthard, McGarrity, Redfern; unpublished
data), thus reducing the incorporation of dTG into DNA despite
higher TGN levels. However, any interpretation of how dTGDNA
relates to RBC TGNs has to be speculative given our limited
understanding of thiopurine metabolism in white blood cells
and transfer of thiopurine metabolites between cell and tissue
compartments. Indeed, the lack of a relationship between dTGDNA
and RBC-TGN has echoes of studies showing a lack of correla-
tion between RBC-TGN levels and biological or clinical
responses.35–37 RBCs have low IMPDH activity38,39 and RBC-
TGNs must, therefore, be derived from liver thioguanine metab-
olized from azathioprine, or remain from immature erythrocytes.
Further studies are needed to test the relationships between
dTGDNA and biological and clinical responses in IBD, and how
dTGDNA levels are affected by the dynamics of thiopurine and
purine metabolism in different cell populations.
Although thiopurines are used extensively as immunosup-
pressants there is uncertainty of the mechanisms involved,
a question that can be addressed by transcriptome analysis of
peripheral blood with respect to immune system markers.
Inhibition of GTP signaling, specifically the RAC1 GTPase which
is elevated in expression in activated T-cells,40 may be one mech-
anism, at least in vitro.23,41,42 However, evidence that this under-
lies clinical responses is lacking43 and interference in RAC1
signalling was not apparent from our RNA-seq data. We found
a clear response with respect to the downregulation of genes
involved in host-defense mechanisms against microorganisms in
LDAA patients. This may result from gene downregulation in
relevant immune cells, or from a thiopurine-induced reduction
of specific immune-cell populations. Whatever the mechanism,
this is consistent with a role of microorganisms and
host-defense interactions in the etiology of IBD. The wide range
of dTGDNA values despite a fairly homogenous LDAA dataset
with respect to GO categories affected implies that dTGDNA
may not be a good biological marker of response.
Despite the similar range of dTGDNA levels to the LDAA
samples, the AZA-treated patients did not show a consistent
transcriptome-response profile. While more extensive studies
are needed to test for potentially confounding effects of bias
from the treatment site, sample batch with respect to the
LDAA/AZA comparisons or the effects of additional drugs on
some patients in the AZA group, the Gene Ontology analysis,
both for the shared and the full lists of differentially expressed
genes, and the small number of shared genes up- or downregu-
lated by either treatment, support the view that there are differ-
ences between LDAA and AZA in their underlying therapeutic
mechanisms. An important caveat for the interpretation of the
LDAA data is that allopurinol may have anti-inflammatory prop-
erties, independently of its effects on thiopurine metabolism, by
scavenging free radicals, or reducing the T-cell activation44
involved in the pathogenesis of IBD.45 Thus, by providing com-
plementary anti-inflammatory effects, the therapeutic value of
allopurinol for IBD may extend beyond merely improving thio-
purine pharmacokinetics.
Two differentially expressed genes may warrant further
investigation. Firstly, the downregulation of GUCY2C was com-
mon to both treatments. This gene is well known for its role in
endotoxin-mediated diarrhoea,24 is a potential colorectal cancer
marker,46 and may be a link between obesity and colorectal can-
cer.47 Although GUCY2C expression has been detected in CD34+
progenitor cells in peripheral blood,48 a possible reflection of
immune system status, the presence of GUCY2C transcripts in
peripheral blood may also be a consequence of IBD disease pro-
cesses. The detection and significant downregulation of GUCY2C
transcripts in the LDAA and AZA patient groups raises questions
about the potential of GUCY2C as a marker of IBD disease status
and response to therapy with thiopurines or other drugs. Secondly,
MENT is associated with lymphomagenesis in mice, and
decreased methylation activity upregulates MENT expression.49
Noting that thiopurines decrease DNMT activity,50 and aside from
the possibility that lower dTGDNA with LDAA may reduce sec-
ondary cancer risk, the evidence for downregulation of MENT by
LDAA suggests that the elevated lymphoma risk associated with
thiopurine therapy in elderly patients51 may be avoided using
LDAA rather than standard-dose azathioprine.
Whatever the mechanism of LDAA versus AZA, recent
data from a small randomized clinical trial suggest that patients
treated with an allopurinol and azathioprine combination have
better response rates than those on AZA.52 Lower dTGDNA and
MMP levels in LDAA-treated patients suggest that LDAA as
a first-line therapy may be the most appropriate for IBD patients,
obviating the need for preselection on the basis of RBC metabo-
lites.12 Further studies of the potential beneficial role of LDAA in
different clinical contexts, such as a reduction in cancer risk, and
to identify the precise mechanisms of action, are badly needed,
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but there is increasing evidence that this could be the initial treat-
ment of choice for patients with IBD for whom immunosuppres-
sion therapy is appropriate.
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